Pharma Report 2012: Get Back in Shape

Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

14    Boehringer Ingelheim    $7.0B    up 9.4%
Global revenue*: $16.5B (14th); down 1.2%

R&D spend*: $3.3B (13th), up 2.0%; 19.8% of rev.

Top brands: Spiriva ($2.4B), Combivent ($1.1B),  Pradaxa ($559M), Aggrenox ($471M), Fluticasone ($352M)

Planned launches: Afatinib (onc.), Vargatef (onc.), volasertib (onc.), BI 10773 (diab.)

Promotional spend: $906M (8th); 12.9% of rev.

Patent expirations: Spiriva Handihaler (2018)

Boehringer Ingelheim is firing on all cylinders, with six products planned to launch over the next two years, the global roll-out of Pradaxa under way and scarcely a patent expiration in sight. The company has a host of oncology and hepatitis C virus treatments in late-stage clinical trials (BI201335/BI207127), and its partnership with Lilly is already bearing fruit on the diabetes front, with Jentadueto having followed Tradjenta to market. The firm has just completed a $350-million expansion in the US, which accounts for 45% of sales. Blood thinner Pradaxa now must fend off competition from J&J/Bayer Xarelto, and maybe soon Pfizer/BMS drug Eliquis (apixaban).
*Global revenue and R&D spend are based on the 2010 financial year, the latest data available at press time.

Back to first page

Page 14 of 21
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.